Table 3.
Variable | N=137 |
---|---|
Time from HBV diagnosis to HBV follow-up, median months (IQR) | 12.0 (59.3) |
Yearly adherence, n (%) | |
ALT monitoring | 60 (44%) |
HBV DNA monitoring | 29 (21%) |
HCC screening | |
AFP | 27 (20%) |
Abdominal imaging | 34 (25%) |
Antiviral therapy at any time, n (%) | 29 (21%) |
Tenofovir | 17/29 (59%) |
Entecavir | 7/29 (24%) |
Lamivudine | 4/29 (14%) |
Interferon | 1/29 (3%) |